

NSCLC EGFR-TARGETED THERAPIES:

The Oncology Pharmacist's Role in Tailoring Therapy and Improving Patient Outcomes

References

1. Aitken M, Kleinrock M, Pennente K, et al. Medicines use and spending in the U.S. – a review of 2015 and outlook to 2020. QuintilesIMS website. April 2016. <http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/medicines-use-and-spending-in-the-us-a-review-of-2015-and-outlook-to-2020>. Accessed March 2017.
2. Approved drugs: cobas® EGFR mutation test v2. U.S. Food & Drug Administration website. June 2, 2016. <https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm504540.htm>. Accessed March 2017.
3. Cancer stat facts: lung and bronchus cancer. The National Cancer Institute website. <https://seer.cancer.gov/statfacts/html/lungb.html>. Accessed March 2017.
4. Costs for Medicare drug coverage. Medicare.gov website. <https://www.medicare.gov/part-d/costs/part-d-costs.html>. Accessed March 2017.
5. Drugs @ FDA: FDA approved drug products: afatinib. U.S. Food & Drug Administration website. October 4, 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201292s010lbl.pdf. Accessed March 2017.
6. Drugs @ FDA: FDA approved drug products: erlotinib. U.S. Food & Drug Administration website. October 18, 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Accessed March 2017.
7. Drugs @ FDA: FDA approved drug products: gefitinib. U.S. Food & Drug Administration website. July 13, 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206995s000lbl.pdf. Accessed March 2017.
8. Drugs @ FDA: FDA approved drug products: osimertinib. U.S. Food & Drug Administration website. September 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208065s002lbl.pdf. Accessed March 2017.
9. Fein AJ. The 2017 economic report on U.S. pharmacies and pharmacy benefit managers. Drug Channels Institute website. February 2017. http://drugchannelsinstitute.com/products/industry_report/pharmacy/. Accessed March 2017.
10. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J Clin Oncol*. 2011;29(21):2866-2874.
11. Harris T. Does large scale DNA sequencing of patient and tumor DNA yet provide clinically actionable information? *Discov Med*. 2010;10(51):144-150.
12. Improving patient medication adherence: a \$290 billion opportunity. The Network for Excellence in Health Innovation website. http://www.nehi.net/bendthecurve/sup/documents/Medication_Adherence_Brief.pdf. Accessed March 2017.
13. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med*. 2015;372(18):1689-1699.
14. Kenfield SA, Wei EK, Stampfer MJ, et al. Comparison of aspects of smoking among the four histological types of lung cancer. *Tob Control*. 2008;17(3):198-204.
15. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2005;352(8):786-792.

16. Mok TS, Wu YL, Garassino MC, et al; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med*. 2017;376(7):629-640.
17. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009;361(10):947-957.
18. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. *Clin Lung Cancer*. 2009;10(4):281-289.
19. Non-small cell lung cancer version 4.2017. National Comprehensive Cancer Network website. January 18, 2017. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 2017.
20. Patient-centered oncology payment: payment reform to support higher quality, more affordable cancer care. The American Society of Clinical Oncology website. May 2015. http://www.asco.org/sites/www.asco.org/files/asco_patient-centered_oncology_payment_final_2.pdf. Accessed March 2017.
21. Ramalingam S, Yang JCH, Lee CK, et al. Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two phase I expansion cohorts. Abstract LBA1_PR. Presented at the European Lung Cancer Conference; April 13-16, 2016. Geneva, Switzerland.
22. Recently – approved devices: patient labeling: cobas® EGFR mutation test v2. U.S. Food & Drug Administration website. June 2016. http://www.accessdata.fda.gov/cdrh_docs/pdf15/P150047c.pdf. Accessed March 2017.
23. Roe S, Long R, King K. Pharmacies miss half of dangerous drug combinations. The Chicago Tribune website. December 15, 2016. <http://www.chicagotribune.com/news/watchdog/druginteractions/ct-drug-interactions-pharmacy-met-20161214-story.html>. Accessed March 2017.
24. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2012;13(3):239-246.
25. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013;31(27):3327-3334.
26. Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. *Lung Cancer*. 2015;90(3):509-515.
27. URAC directory of accredited companies. URAC website. <https://accreditnet2.urac.org/UracPortal/directory/directorysearch>. Accessed March 2017.
28. Wu YL, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. *Lung Cancer*. 2017;104:119-125.
29. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol*. 2015;16(2):141-151.
30. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*. 2011;12(8):735-742.